Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

152 results about "Dextromethorphan Hydrobromide" patented technology

The hydrobromide salt form of dextromethorphan, a synthetic, methylated dextrorotary analogue of levorphanol, a substance related to codeine and a non-opioid derivate of morphine. Dextromethorphan exhibits antitussive activity and is devoid of analgesic or addictive property. This agent crosses the blood-brain-barrier and activates sigma opioid receptors on the cough center in the central nervous system, thereby suppressing the cough reflex.

Preparation method for daytime-taken softgel for treating cold

The invention discloses a preparation method for a daytime-taken softgel for treating a cold. The preparation method comprises the following steps: A, preparation of a gelatin liquor: dissolving plasticizer in water, adding into a gelatin melting tank, adding gelatin, stirring to dissolve, adding coloring agent into water, stirring uniformly to obtain a pigment solution, adding the pigment solution into an obtained gelatin solution, stirring and vacuumizing to exhaust air bubbles, so as to obtain the gelatin liquor; B, preparation of contents: adding mixed polyethylene glycol and polyhydric alcohol into polyvidone, stirring to dissolve, adding acetaminophen, stirring to obtain a suspension, adding into a proportioning tank, vacuumizing, filling with inert gas, heating to dissolve, cooling, adding dextromethorphan hydrobromide and phenylephrine hydrochloride, vacuumizing, and keeping the temperature to dissolve, so as to obtain a content solution; C preparation of the softgel: adding the gelatin liquor and the content solution into a pelleting machine respectively, pelleting, drying, pellet plastering and packaging. The invention aims to provide the preparation method for the daytime-taken softgel which is used for treating the cold, and is simple in process, convenient to manufacture and good in product stability.
Owner:安士制药(中山)有限公司

Pharmaceutical composition for treating cold in children and preparation method thereof

The invention provides a pharmaceutical composition for treating cold in children and a preparation method thereof. The pharmaceutical composition comprises the following components and medicine prepared in ratio: dextromethorphan hydrobromide, chlorphenamine maleate, ammonium chloride, seasoning agent, antiseptic and water, wherein the dextromethorphan hydrobromide is coated by beta-cyclodextrin and is prepared into preparation; the clathrate compound improves the mouthfeel and the water solubility of the dextromethorphan, and realizes delayed release effect so that, after being administrated, the dextromethorphan continuously develops functions of relieving cough in 2-6h, and the ammonium chloride is rapidly released for dispelling phlegm within 1h, thereby effectively solving the problem of antagonism between the dextromethorphan and the ammonium chloride. The pharmaceutical composition can be prepared into syrup, oral solution and drop which are easily accepted by the children. The pharmaceutical composition is simple in preparation technique, easy in production and operation, good in producing stability, reliable in product quality, sweet in taste, good in compliance, and acceptable by children; the dose is accurately measured according to age of the children; and the pharmaceutical composition can safely and rapidly eliminate or relieve cold symptoms of the children, such as cough, excessive and thick phlegm, pharyngalgia, rhinobyon, rhinorrhoea, sternutation and the like caused by infection of upper respiratory tract and allergic reaction.
Owner:BEIJING YIYUE MEDICAL TECH

Method for determining related substances of pharmaceutical preparation containing acetaminophen, dextromethorphan hydrobromide and phenylephrine hydrochloride

The invention discloses a method for determining related substances of a pharmaceutical preparation containing acetaminophen, dextromethorphan hydrobromide and phenylephrine hydrochloride. The determination method disclosed by the invention is performed by adopting a high performance liquid chromatography; proper HPLC chromatographic conditions are screened out; and 10 related substances of dextromethorphan impurities I, dextromethorphan impurities II, dextromethorphan impurities III, dextromethorphan impurities IV, norepinephrine, a phenylephrine related substance F, a 4,6 diol isoquinoline analogue, a phenylephrine related substance C, 3-hydroxybenzaldehyde and a phenylephrine related substance G in the pharmaceutical preparation of acetaminophen, dextromethorphan hydrobromide and phenylephrine hydrochloride can be simultaneously determined under the same condition. Effective separation of a variety of impurities can be achieved, and detection time and detection cost are greatly saved. The method can be used for quality research and quality control of pharmaceutical preparation products containing the acetaminophen, the dextromethorphan hydrobromide and the phenylephrine hydrochloride.
Owner:安士制药(中山)有限公司

Dextromethorphan hydrobromide sustained-release suspension and preparation method thereof

The invention discloses a dextromethorphan hydrobromide sustained-release suspension. The suspension is prepared from, by mass, 85-95% of a suspension matrix, 0.5-1.5% of coated resin, 0.1-0.5% of drug-loaded resin, 0.01-0.08% of EDTA, 0.1-0.3% of a surface active agent and the balance water, wherein the drug-loaded resin is prepared from a dextromethorphan hydrobromide crude drug, sodium polystyrenesulfonate type cation exchange resin and purified water; the coated resin is prepared from impregnating resin, dichloromethane, vegetable oil, ethyl cellulose and acetone, and the impregnating resin is prepared from polyethylene glycol, purified water and the prepared drug-loaded resin. The invention further discloses a preparation method of the dextromethorphan hydrobromide sustained-release suspension. The sustained-release effect is good, the drug treating effect is lasting, the treatment effect is good, the number of drug applying times can be obviously reduced, the problems that a solid sustained-release preparation is poor in taste, difficult to swallow and inaccurate in fractional dose are solved, and the dextromethorphan hydrobromide sustained-release suspension is convenient for children patients to take.
Owner:JIANGSU SIHUAN BIOENGINEERING PHARM CO LTD

Spongy dextromethorphan hydrobromide film agent with micro-pore and preparation method thereof

The invention discloses a spongy dextromethorphan hydrobromide film agent with micro-pore and a preparation method of the film agent; the spongy dextromethorphan hydrobromide film agent with micro-pore comprises the following components: a dextromethorphan hydrobromide, a water-soluble polymer material, and a water-insoluble micro-powder dispersed in the water-soluble polymer material; the water-soluble polymer material is any two of HPMC (hydroxy propyl methyl cellulose), PVA (polyvinyl alcohol), HPC (hydroxy propyl cellulose), CMC-NA (sodium carboxyl methyl cellulose), PVP (polyvinyl pyrrolidone), sodium alginate or PEO (polyethylene oxide), and wherein one is a lower molecular weight water-soluble polymer material with molecular weight of 10, 000-200, 000 Dalton, the other one is a higher molecular weight water-soluble polymer material with molecular weight of 200, 000-10, 000, 000 Dalton. According to the invention, effects are very significant; films are dissolved fast through the lower molecular weight water-soluble polymer material, physical strength and toughness of films are ensured through the higher molecular weight water-soluble polymer material so as to realize the purpose of quick release and ensure strength of films.
Owner:SHANGHAI MODERN PHARMA ENG INVESTIGATION CENT +1

Method of treating commercial grade products to remove undesirable odors and flavors

A method of treating antimicrobial products, dairy products, pharmaceutical products and other products having offensive tastes or odors to remove the off-odors and off-tastes from the products. The method involves exposing a selected commercial grade product that contains a small amount of free acid impurities to an ammonia gas. The ammonia gas reacts with the free acid impurities to convert the free acids into ammonium salts, thereby reducing or eliminating the off-flavor and off-odor of the product. The products to be treated include antimicrobial products selected from the group consisting of sodium benzoate, calcium benzoate, potassium benzoate, sodium diacetate, paraben, niacin, calcium acetate, calcium diacetate, sodium sorbate, calcium sorbate, potassium sorbate, sodium propionate, calcium propionate, potassium propionate and mixtures thereof; dairy products selected from the group consisting of casein, whey, skim milk powder, and calostrum; pharmaceutical products selected from the group consisting of acetaminiphen, aspirin, ibuprophen, dextromethorphan hydrobromide, guaejenesin, paracetamol, and sodium erythorbate; and various other products selected from the group consisting of butylate hydroxy tolulene, polydextrose powder, sodium acid sulfate, and sodium diacetate. The common characteristic of the commercial grades of each of these products is that they contain a small amount of free acid impurities that react favorably with ammonia gas.
Owner:TILLIN

Slow-release type solid corrosion inhibitor and preparation method thereof

The invention discloses a slow-release type solid corrosion inhibitor and a preparation method thereof. The solid corrosion inhibitor is prepared from the following materials: 60 percent to 70 percent of a main material and 30 percent to 40 percent of an auxiliary material; the main material is formed by compounding three components of amantadine hydrochloride, diphenhydramine hydrochloride and dextromethorphan hydrobromide according to a molar mass ratio of 2 to 2 to 1; the auxiliary material is formed by compounding carnauba wax, pregelatinized starches, polyvinylpyrrolidone, microcrystalline cellulose, carboxymethyl starch sodium and stearic acid according to a mass ratio of 3 to 3 to 2 to 2 to 2 to 1. The preparation method comprises the following steps: after mixing the auxiliary material evenly according to a formula ratio, stirring and heating to 80 DEG C to 90 DEG C, melting the auxiliary material, slowly adding the main material, which is mixed evenly according to a formula ratio, into the molten auxiliary material, continuously stirring and heating, after sufficiently mixing the main material and the auxiliary material evenly, putting into a mould for compression molding, and cooling to obtain a finished product of the solid corrosion inhibitor. The corrosion inhibitor is low in usage amount, long in release period, good in corrosion inhibiting effect, simple in preparation and putting process, and suitable for anticorrosion for an oil well and an underground tube and rod.
Owner:CHINA UNIV OF PETROLEUM (EAST CHINA)

Method for determining dissolution rate of medicinal preparation containing acetaminophen, dextromethorphan hydrobromide and doxylamine succinate

The invention discloses a method for determining a dissolution rate of a medicinal preparation containing acetaminophen, dextromethorphan hydrobromide and doxylamine succinate. The method comprises the following steps of: (1) adding medicinal preparation containing acetaminophen, dextromethorphan hydrobromide and doxylamine succinate into a dissolution medium for dissolution treatment, performing sampling and filtering to obtain dissolution liquid; (2) detecting the contents of acetaminophen, dextromethorphan hydrobromide and doxylamine succinate in the dissolution liquid; and (3) and determining the dissolution rate of the medicinal preparation according to the detection result of the step (2). The method can effectively simulate the dissolution behavior in vivo in vitro, can determine the dissolution rate of the soft capsule containing acetaminophen, dextromethorphan hydrobromide and doxylamine succinate, and provides technical support for the research and development and quality control of medicaments. The method can simultaneously determine the dissolution results of the three substances under the same condition, greatly saves the detection time and the detection cost, and has good accuracy and reproducibility.
Owner:安士制药(中山)有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products